A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/02/2006	WO2006031314A3 Use of tyrphostins to stimulate neurite outgrowth
11/02/2006	WO2006020618A8 Compositions and methods for treating leukemia
11/02/2006	WO2005117872A3 Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
11/02/2006	WO2005113515A8 Pyrimidines for use as plk inhibitors
11/02/2006	WO2005110384B1 Apiary veterinary composition
11/02/2006	WO2005108349A3 Process for preparing atazanavir bisulfate and novel forms
11/02/2006	WO2005107748A3 Method of tonic treatment with oxyphenbutazone derivatives
11/02/2006	WO2005103034A8 Novel piperidine substituted diaminothiazoles
11/02/2006	WO2005092442B1 Method and compositions for treatment of chronic neuropathic pain
11/02/2006	WO2005092385A3 Combination therapy of azd2171 and a taxane
11/02/2006	WO2005092384A3 Combination therapy with azd2171 and a platinum anti-tumour agent
11/02/2006	WO2005092303A3 Combination therapy with azd2171 and 5-fu and/or cpt-11
11/02/2006	WO2005086641A3 Anti-infectious hydrogel compositions
11/02/2006	WO2005084637A3 Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof
11/02/2006	WO2005079396A3 O,o'-amidomalonate and n,o-amidomalonate platinum complexes
11/02/2006	WO2005070080A3 Methods of using zonisamide as an adjunctive therapy for partial seizures
11/02/2006	WO2005041899A3 Orally available sphingosine 1-phosphate receptor agonists and antagonists
11/02/2006	US20060248605 Beta-amyloid peptide-binding proteins and polynucleotides encoding the same
11/02/2006	US20060248601 Modification of organelle metabolism by unc-51-like kinases roma1 or 2tm proteins
11/02/2006	US20060247451 Crystalline base of citalopram
11/02/2006	US20060247448 zearalenone-like macrolides, used to to inhibit nuclear factor kappa-beta (NF- kappa B) activation, as sucnscreen agents and in the treatment of inflammatory or autoimmune disorders and disorders involving malignancy or increased angiogenesis
11/02/2006	US20060247439 Mchir antagonists
11/02/2006	US20060247437 Preparation of ketone amides
11/02/2006	US20060247435 Novel intermediates for linezolid and related compounds
11/02/2006	US20060247432 Synthesis of 5-Azacytidine
11/02/2006	US20060247321 Abnormal Cannabidiols as agents useful in combination therapy for lowering intraocular pressure
11/02/2006	US20060247320 Compounds for inhibiting KSP kinesin activity
11/02/2006	US20060247319 Preparation of 4-bromotetrahydrofluoreneones
11/02/2006	US20060247318 Small molecule inhibitors of STAT3 and the uses thereof
11/02/2006	US20060247317 Method for treating peripheral vascular diseases
11/02/2006	US20060247316 Food supplement
11/02/2006	US20060247315 Method of treating intestinal disorders with citrulline
11/02/2006	US20060247314 Substituted tetralins and indanes
11/02/2006	US20060247313 administering to a osteoporosis patient an effective amount of a amino acid formulation containing 10 to 40 parts by weight of L-arginine or L-glutamine; 5 to 20 parts of L-valine; 8 to 30 parts of L-isoleucine; and10 to 35 parts of L-leucine; regeneration of tendon and ligamet; antiaging of skin
11/02/2006	US20060247312 Composition comprising free amino acids
11/02/2006	US20060247311 Using synergistic mixture of 1-(aminomethyl)-cyclohexane acetic acid or (1-aminomethyl-3,4-dimethylcyclopentyl)acetic acid and smooth muscle moderator including antimuscarinic agent Tolterodine
11/02/2006	US20060247310 Body temperature elevating agents
11/02/2006	US20060247309 Compounds for the treatment of metabolic disorders
11/02/2006	US20060247308 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
11/02/2006	US20060247307 imino compound as antiinflammatory agent, anticarcinogenic agent for treating chronic inflammation and cancers; activating peroxisome proliferator-activated receptor
11/02/2006	US20060247306 Radiation protection by gamma-tocotrienol
11/02/2006	US20060247305 Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
11/02/2006	US20060247304 Pharmaceutical compositions for the treatment of pain
11/02/2006	US20060247303 7H-dibenzo[b,g][1,5]dioxocin-5-one derivatives and use thereof
11/02/2006	US20060247302 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
11/02/2006	US20060247300 Aminocyclohexyl ether compounds and uses thereof
11/02/2006	US20060247299 administering HMG-CoA reductase inhibitor; for treatment of diabetes and complications caused by insulin resistance syndrome
11/02/2006	US20060247298 {[((1E)-{4-[3-(4-tert-butylphenoxy)prop-1-ynyl]phenyl}methylidene)amino]oxy}acetic acid; plasminogen activator inhibitor, anticoagulant; venous, arterial, cerebral, and deep vein thrombosis, atrial fibrillation, pulmonary fibrosis, myocardial ischemia, atherosclerotic plaque formation
11/02/2006	US20060247297 Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases
11/02/2006	US20060247296 Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
11/02/2006	US20060247295 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indole-4-one (CBI) with incorporated alkylating domain; in vivo drug-cleavable substrate conjugates that are potent cytotoxins; antiproliferative, anticarcinogenic agent; leukemia; bone marrow and mucosal toxicity; chronic cardiac and neurological toxicity
11/02/2006	US20060247294 angiogenesis inhibitors; as antitumor agents; kinase inhibitors like vascular endothelial growth factor receptors antagonists
11/02/2006	US20060247293 suppressing death of optic nerve cells during ocular hypertension in patient with glaucoma via administering 3-methyl-1-phenyl-2-pyrazolin-5-one; drops, sustained release formulations
11/02/2006	US20060247292 Benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents
11/02/2006	US20060247291 (2S)-2-Amino-4-ethyl-2-methylhexanoic acid or a pharmaceutically acceptable salt thereof as analgesic agent
11/02/2006	US20060247290 Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics
11/02/2006	US20060247289 Certain chemical entities, compositions, and methods
11/02/2006	US20060247288 Method for manufacturing isoxazole derivative or dihydroisoxazole derivative
11/02/2006	US20060247287 Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses
11/02/2006	US20060247286 Oxazolidinone antibiotics and derivatives thereof
11/02/2006	US20060247285 Novel heterocyclic diphenyl ethers
11/02/2006	US20060247284 Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy
11/02/2006	US20060247282 Methods for using amino acids with affinity for the alpha2delta-protein
11/02/2006	US20060247281 Process for halomethyl ethers of hydroxyiminomethyl quaternary pyridinium salts
11/02/2006	US20060247280 Non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis; 3-Benzyl-5-(benzylthio)-1,2,4-triazole
11/02/2006	US20060247279 polymorphic form rosiglitazone maleate, used for prophylaxis of diabetes in humans; crystal structure
11/02/2006	US20060247278 Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
11/02/2006	US20060247277 Polymorphs of s-omeprazole
11/02/2006	US20060247276 Benzofuranyl alkanamine derivatives and uses thereof
11/02/2006	US20060247275 Treating hyperproliferative disorders such as gastrointestinal cancer, breast cancer, head cancer, or neck cancer; N-(4-trifluoromethoxyphenyl) 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide
11/02/2006	US20060247274 N,N-bis(3-Phenoxycinnamyl)Glu(O-t-Bu)-OMe; demonstrate competitive binding with the natural ligand; ease administration, cost less and facilitate patient compliance; USEFUL IN TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH ERYTHROPOIETIN RECEPTOR
11/02/2006	US20060247273 Carbamoyl-type benzofuran derivatives
11/02/2006	US20060247272 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds
11/02/2006	US20060247271 Sulphonyl hydroxamic acid derivatives as inhibitors of s-cd23
11/02/2006	US20060247270 3-Substituted-2(Arylalkyl)-1-Azabicycloalkanes and Methods of Use Thereof
11/02/2006	US20060247269 Thienopyridone derivatives as kinase inhibitors
11/02/2006	US20060247268 N-sulfonylaminothiazole
11/02/2006	US20060247267 SNS-595 and methods of using the same
11/02/2006	US20060247266 Nitrogen-containing tricyclic compounds
11/02/2006	US20060247265 Therapies for treating disorders of the eye
11/02/2006	US20060247264 Modulators of the Glucocorticoid Receptor
11/02/2006	US20060247263 Substituted heterocyclic compounds and methods of use
11/02/2006	US20060247262 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors
11/02/2006	US20060247261 Pyrimidine compounds
11/02/2006	US20060247260 Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists
11/02/2006	US20060247259 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective
11/02/2006	US20060247258 Use of levocetirizine for the treatment of persistent allergic rhinitis
11/02/2006	US20060247257 Combination
11/02/2006	US20060247256 Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
11/02/2006	US20060247255 Method for preparing a stable gatifloxacin composition
11/02/2006	US20060247254 6,7-Dihydro-5H-cyclopenta[b]pyridine and 5,6,7,8-tetrahydroquinoline compounds; 5-HT2c receptor agonists; to treat diseases like obesity, depression, atypical depression, anxiety, epilepsy, lower urinary tract dysfunction; less toxic; selectivity
11/02/2006	US20060247253 Novel heterocyclic NF-kB inhibitors
11/02/2006	US20060247252 Augmented cognitive training
11/02/2006	US20060247251 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof
11/02/2006	US20060247250 Pyrimidine inhibitors of kinases
11/02/2006	US20060247249 Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers
11/02/2006	US20060247248 Sigma-1 receptor ligand with acetylcholinesterase
11/02/2006	US20060247247 Pyrazole-amine compounds useful as kinase inhibitors
11/02/2006	US20060247246 3-{[(5,5a,8a,9)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl]amino}-1-methyl-1H-pyrrole-2,5-dione; anticarcinogenic agent; inhibiting catalytic activity of topoisomerase II by stabilization of cleavable complex; better soluble and tolerated
11/02/2006	US20060247245 Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands

1 ... 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 4043 4044 ... 7860